Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3299-3306

  Crandon, Jared L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; AZTREONAM; METALLO BETA LACTAMASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PROTEIN BINDING; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ENZYME SYNTHESIS; FEMALE; IMMUNOCOMPETENCE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SINGLE DRUG DOSE;

ANIMALS; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; AZTREONAM; BACTERIAL PROTEINS; BETA-LACTAMASES; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84879022343     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01989-12     Document Type: Article

References (19)

1. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE. 2010. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin. Infect. Dis. 50:625-663.
2. Rotstein C, Evans G, Born A, Grossman R, Light RB, Magder S, McTaggart B, Weiss K, Zhanel GG. 2008. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can. J. Infect. Dis. Med. Microbiol. 19:19-53. (Pubitemid 351547672)
3. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC. 2005. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41:1373-1406. (Pubitemid 41581713)
4. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. 2009. Characterization of a new metallo-β-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53:5046-5054.
5. Cornaglia G, Giamarellou H, Rossolini GM. 2011. Metallo-betalactamases: a last frontier for beta-lactams? Lancet Infect. Dis. 11:381-393.
6. Queenan AM, Bush K. 2007. Carbapenemases: the versatile β-lactamases. Clin. Microbiol. Rev. 20:440-458, table of contents.
7. Livermore DM, Mushtaq S, Warner M, Miossec C, Woodford N. 2008. NXL104 combinations versus Enterobacteriaceae with CTX-M extendedspectrum beta-lactamases and carbapenemases. J. Antimicrob. Chemother. 62:1053-1056.
8. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55:390-394.
9. Clinical Laboratory Standard Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI publication M07-A9. Clinical Laboratory Standard Institute, Wayne, PA.
10. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, Nicolau DP. 2012. Comparative in vitro and in vivo efficacies of human simulated exposures of ceftazidime and ceftazidimeavibactam against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 56:6137-6146.
11. Vinks AA, van Rossem RN, Mathot RA, Heijerman HG, Mouton JW. 2007. Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using Monte Carlo simulation. Antimicrob. Agents Chemother. 51:3049-3055. (Pubitemid 350067507)
12. Andes D, Craig WA. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379. (Pubitemid 28420381)
13. Li J, Knebel W, Riggs M, Zhou D, Nichols W, Das S. 2012. Population pharmacokinetic modeling of ceftazidime and avibactam in healthy volunteers and patients with complicated intra-abdominal infection, abstr. A-634. 52nd Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
14. Pilkiewicz FG, Remsburg BJ, Fisher SM, Sykes RB. 1983. High-pressure liquid chromatographic analysis of aztreonam in sera and urine. Antimicrob. Agents Chemother. 23:852-856. (Pubitemid 13104020)
15. Wiskirchen DE, Crandon JL, Furtado GH, Williams G, Nicolau DP. 2011. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-β-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55:3220-3225.
16. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86. (Pubitemid 44968990)
17. Drusano GL. 2010. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved antimethicillin- resistant Staphylococcus aureus activity. J. Antimicrob. Chemother. 65(Suppl. 4):iv33-iv39.
18. Bush K. 2012. Improving known classes of antibiotics: an optimistic approach for the future. Curr. Opin. Pharmacol. 12:527-534.
19. Craig WA. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am. 17:479-501. (Pubitemid 38029149)